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A Pragmatic Trial of E-Cigarettes, Incentives, and Drugs for Smoking
Cessation
Abstract
In a trial examining five approaches to smoking cessation among over 6,000 U.S. employees, financial
incentives combined with free cessation aids were more effective at getting employees to stop smoking than
free cessation aids alone. Specifically, the most effective intervention (free cessation aids plus $600 in
redeemable funds) helped 2.9% of participants stop smoking through six months after their target quit date;
this rate jumped to 12.7% among participants who actively engaged in the trial and were more motivated to
quit. For employees with access to usual care (information and a free motivational text messaging service),
offering free cessation aids or electronic cigarettes (e-cigarettes) did not help them quit smoking.
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THE QUESTION
Recognizing the health and economic costs of employees who smoke, 
most large U.S. companies offer smoking-cessation programs, nearly 
half of which are paired with financial incentives for employees who 
successfully stop smoking. However, the benefits offered by workplace 
smoking-cessation programs vary considerably, and there is limited 
evidence about the optimal design of smoking cessation interventions. 
The authors conducted a five-group randomized, controlled trial to 
compare usual care (access to information regarding the benefits of 
smoking cessation and a motivational text-messaging service) with four 
smoking-cessation interventions to determine which is most effective 
at helping employees stop smoking. The four interventions were free 
cessation aids (nicotine-replacement therapy or pharmacotherapy, with 
e-cigarettes if standard therapies failed); free e-cigarettes, without a
requirement that standard therapies had been tried; free cessation aids
plus $600 in rewards for sustained abstinence, and; free cessation aids
plus $600 in redeemable funds, deposited in a separate account for
each participant, with money removed from the account if cessation
milestones were not met. They compared quit rates between groups
and the costs associated with each intervention.
THE FINDINGS
Among 6,131 smokers from 54 companies invited to enroll, 6,006 enrolled 
and were randomized to usual care or one of the four intervention groups 
(125 opted out). Of the enrollees, 1,191 (19.8%) were “engaged,” meaning 
they logged into the trial website at least once during the program. 
Engaged participants were more educated, more motivated to quit, more 
likely to be female, and more often past or present users of e-cigarettes 
than participants who did not actively engage in the trial.
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Overall, 80 (1.3%) participants stopped smoking through six months after 
their target quit date. The rate of sustained smoking abstinence was 0.1% 
in the group that received usual care, 0.5% in the free cessation aids group, 
1.0% in the free e-cigarettes group, 2.0% in the rewards group, and 2.9% 
in the redeemable deposit group (Figure 1). The authors found three 
meaningful comparisons between groups: redeemable deposits combined 
with free cessation aids were more effective than either free cessation aids 
or free e-cigarettes alone, and rewards combined with free cessation aids 
were more effective than free cessation aids alone. Important to note are 
the negative findings: free cessation aids and free e-cigarettes were no 
more effective than usual care.  About half of the participants who stopped 
smoking for six months after their target quit date were also smoke-free at 
12 months (six months after interventions ended).
Engaged participants had sustained smoking abstinence rates that were 
four to six times as those who did not actively engage: 2.9% in the free 
cessation aids group, 4.8% in the free e-cigarettes group, 9.5% in the rewards 
group, and 12.7% in the redeemable deposit group (Figure 1). The relative 
effectiveness of the interventions also applied to engaged participants.
The average cost per participant was lowest in the usual care group 
(<$1) and highest in the redeemable deposit group ($101). The cost per 
successful quit was lower in the rewards ($3,623) and redeemable deposit 
($3,461) groups than in the free e-cigarettes ($5,416) or free cessation aids 
($7,798) group.
THE IMPLICATIONS
Previous randomized, controlled trials included employees who were 
interested in quitting smoking. This trial examined the success of 
smoking cessation interventions when offered to all smokers, not just 
those interested in quitting. This study design produced lower cessation 
rates overall compared to previous workplace studies on employees 
who were motivated to quit (though found comparable results among 
engaged participants). Despite low rates overall, incentive programs 
may still be useful for employers, as most costs are incurred only if 
employees successfully quit, and overall costs are lower than the extra 
cost of employing smokers.
An important finding is that free cessation aids, a cornerstone of many 
employer wellness programs, did not significantly improve quit rates. 
This trial also provided robust evidence that offering free e-cigarettes 
did not result in higher quit rates than traditional smoking cessation 
aids, nor improve quit rates among employees offered information 
and access to a motivational text messaging service. The authors did 
not assess efficacy of the use of these products, or the possibility that 
e-cigarettes reduce the harms associated with conventional smoking.
However, a recent expert report suggests that e-cigarettes would only
reduce short-term adverse health effects of smoking if they lead to
complete smoking cessation.
This trial showed that financial incentives promoted smoking cessation 
even when free cessation aids were routinely available. These results, 
considered alongside those from previous trials, suggest that incentives 
at least triple cessation rates regardless of whether free cessation aids 
are offered. The authors found that redeemable deposit contracts, in 
which participants would lose incentives if they continued smoking, 
were not significantly better than incentive programs structured as pure 
rewards. Nonetheless, the observation that this loss framing produced 
nominally higher rates of quitting at nominally lower costs per quit may 
motivate employers that are planning incentive programs to consider 
the use of loss framing.
THE STUDY
This study was done in partnership with the Vitality group, a health 
and wellness company (a subsidiary of Discovery, the South African 
Insurance Company). Eligible participants were employees and their 
spouses at 54 companies that used Vitality as part of their wellness 
programs, were at least 18 years old, and reported current smoking on 
health risk assessment within the previous year. Enrollment proceeded 
in two phases: 2,229 eligible participants were identified from nine 
companies in the first phase, and 3,902 eligible participants from 45 
companies were identified in the second phase.
Potential participants were notified by email on at least four occasions 
that they had been selected to participate. If participants didn’t opt 
out, they were enrolled and randomly assigned to usual care or to 
Figure 1.   
Sustained Smoking Abstinence at 6 Months after the 
Target Quit Date
Source: New England Journal of Medicine
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an intervention. All participants were informed of usual care resources (information 
and access to a free motivational text-messaging program); those randomized to 
intervention groups were also offered one of four additional programs.
The authors measured the rate of sustained smoking abstinence at six months after 
the target quit date for each group. Successful smoking abstinence required that 
participants report smoking cessation on a survey at 1, 3, and 6 months, which was 
biochemically confirmed with a urine or blood sample. Participants assigned to the 
rewards and redeemable deposit groups were eligible to earn $100, $200, and $300 at 
1, 3, and 6 months after the quit date, respectively, if their samples were negative for 
nicotine metabolites. The authors compared quit rates between groups, designating 
the free cessation aids group as the primary comparator against which the other four 
groups were compared. Four other between-group contrasts were done, resulting 
in eight total comparisons. They calculated and compared each intervention’s cost 
(including incentives disbursed, evaluation and payment for blood and urine samples, 
and cessation aids).
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